The mosquito-borne disease dengue (DEN) is caused by four serologically and genetically related viruses, termed DENV-1 to DENV-4. Infection with one DENV usually leads to acute illness and results in lifelong homotypic immunity, but individuals remain susceptible to infection by the other three DENVs. The lack of a small-animal model that mimics systemic DEN disease without neurovirulence has been an obstacle, but DENV-2 models that resemble human disease have been recently developed in AG129 mice (deficient in interferon alpha/beta and interferon gamma receptor signaling). However, comparable DENV-1, -3, and -4 models have not been developed. We utilized a non-mouse-adapted DENV-3 Thai human isolate to develop a lethal infection model in AG129 mice. Intraperitoneal inoculation of six to eight-week-old animals with strain C0360/94 led to rapid, fatal disease. Lethal C0360/94 infection resulted in physical signs of illness, high viral loads in the spleen, liver, and large intestine, histological changes in the liver and spleen tissues, and increased serum cytokine levels. Importantly, the animals developed vascular leakage, thrombocytopenia, and leukopenia. Overall, we have developed a lethal DENV-3 murine infection model, with no evidence of neurotropic disease based on a non-mouse-adapted human isolate, which can be used to investigate DEN pathogenesis and to evaluate candidate vaccines and antivirals. This suggests that murine models utilizing non-mouse-adapted isolates can be obtained for all four DENVs.
D
engue (DEN) is a mosquito-borne disease that is endemic in most tropical countries and causes at least 100 million clinical infections each year, including 2.1 million cases of severe DEN fever (DF) and 500,000 cases of DEN hemorrhagic fever (DHF) (1) . DEN is caused by four serologically and genetically related viruses, or serotypes, termed DENV-1 to DENV-4, which are members of the genus Flavivirus, family Flaviviridae. This family contains other medically important mosquito-borne viruses, including West Nile, yellow fever, and Japanese encephalitis viruses.
Primary infection with one DENV usually leads to a self-limiting acute fever with headache, retro-orbital pain, myalgia, vomiting, or maculopapular rash, followed by lifelong homotypic immunity. However, the individual remains susceptible to infection by one or more of the other three DENVs. Dengue hemorrhagic fever is a severe form of the disease that is associated with plasma leakage, thrombocytopenia, mucosal bleeding, and gastrointestinal hemorrhage. while dengue shock syndrome (DSS) includes DHF symptoms accompanied by hypovolemic shock. Additionally, severe disease is associated with high viremia levels. Severe outcomes are possible upon a second DENV infection due to immune enhancement that may involve antibody-dependent enhancement (ADE), cytotoxic cells, and/or a cytokine storm (2, 3) . One of the implications of immune enhancement is that a vaccine against DEN must protect from infection by all four DENVs simultaneously. Currently, there are no licensed vaccines or any antiviral drugs to control DEN.
A major obstacle to the development of vaccines and therapeutics for DENV infection has been the lack of appropriate animal models that mimic the DENV disease of humans. DENV is transmitted by Aedes mosquitoes to humans in the urban cycle, while the sylvatic (jungle) transmission cycle involves mosquitoes and monkeys. Therefore, nonhuman primates (NHP) have been studied as a model of nonlethal infection, as the majority of the studies have not shown clinical signs of infection; however, promising new models include some features of human disease, and have been reviewed recently (4, 5, 6) . Notwithstanding the limitations, the NHP model has been used to test live attenuated and recombinant vaccine candidates (7, 8) .
Initial attempts to develop small-animal models involved adaptation of human virus isolates by passage in suckling-mouse brain, which results in a virus that causes lethal neurological disease, which is uncommon in human DENV infections (9) . Subsequent models with mouse brain-adapted strains of DENV-2 and DENV-3 did not show neurological manifestations of disease. These studies examined disease in wild-type mice and in mice deficient in components of the immune response to study interferon gamma (IFN-␥) protection during DENV infection (10, 11) . The mice developed a lethal infection and clinical signs of human disease, such as viremia and systemic cytokine responses. However, mouse-adapted strains lose their ability to cause human disease on passage (12) , presumably due to genetic mutations, as evidenced by several studies (13, 14, 15, 16) .
Recently, a DENV-2 model has been described in AG129 mice (deficient in IFN-␣/␤ and -␥ receptor signaling). Initial studies made the critical observation that the mouse brain-adapted DENV-2 strain New Guinea C was lethal in AG129 mice following intraperitoneal (i.p.) inoculation (17) . A disseminated, nonneurotropic DENV-2 mouse model was subsequently developed in AG129 mice by inoculation with D2S10, a strain that was developed by alternately passaging a parent strain PL046 (10 times) between mice (intravenously) and mosquito cells. A high inoculum (10 7 PFU) leads to systemic infection, tumor necrosis factor alpha (TNF-␣)-mediated disease, and lethality (18) . Additional studies focused on tissue tropism of DENV-2 (19, 20, 21) . More recently, another DENV-2 strain was found to be lethal in AG129 mice; D2Y98P was derived from a human Singaporean isolate in 1998 following approximately 20 passages in Aedes albopictus C6/36 cells, and it leads to increased cytokine levels, pathological changes in the liver, spleen, and intestine, and splenomegaly, among other signs of illness (22) . Extensive reviews on DEN mouse models have recently been published (23, 24, 25) . The DENV-2 models have made a significant impact on the field by providing a platform to model lethal, systemic infection in AG129 mice and to study virus tropism. Furthermore, intact adaptive immunity provides a platform to investigate the specific antibody response.
Relevant animal models are important for the evaluation of vaccine candidates and potential novel antivirals. NHP and humanized mouse models contain some signs of human infection but are not lethal. Immunocompromised mouse models have seen the greatest success with DENV-2, but nonneurovirulent, lethal murine models remain to be developed for DENV-1, -3, and -4. Therefore, we sought to develop a murine infection model of DENV-3. In the present study, we characterized the lethal, systemic infection model that results from infection with the nonadapted, low-passage-number Thai human isolate C0360/94 in AG129 mice.
MATERIALS AND METHODS
Cell culture. Monkey kidney Vero cells were maintained at 37°C in 5% CO 2 in minimum essential medium (MEM) supplemented with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U/ml penicillin-100 g/ml streptomycin, and 8% bovine growth serum (BGS). C6/36 mosquito cells were maintained at 28°C in MEM supplemented with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U/ml penicillin-100 g/ml streptomycin, 1 mM sodium pyruvate, tryptose phosphate buffer, and 10% fetal bovine serum.
Virus. DENV-3 strain C0360/94 was acquired from the World Reference Center of Emerging Viruses and Arboviruses (WRCEVA) at the University of Texas Medical Branch (UTMB). Seed stocks were amplified 2 to 4 times in C6/36 cells with 2% fetal bovine serum (FBS). For AG129 infection, virus was harvested and concentrated using a 100,000-molecular-weight-cutoff (MWCO) Amicon centrifugal filter at 3,000 rpm and 4°C for 20 min and then quantified by focus assays in Vero cells. Briefly, cells in 12-well plates were infected with 10-fold virus dilutions for 30 min before overlay with MEM containing 2% BGS-0.8% carboxymethyl cellulose and incubated for 5 days at 37°C. Wells were fixed with acetone-methanol, and foci were visualized by immunostaining with the pan-mosquito-borne flavivirus monoclonal antibody 4G2 or DENV-3-specific mouse immune ascitic fluid. Virus titers are expressed as focus-forming units (FFU)/ml.
Mouse infection. AG129 mice were bred and maintained at the animal facility at the University of Texas Medical Branch (UTMB). Experiments were approved by the UTMB Institutional Animal Care and Use Committee and performed according to institutional guidelines. Six-, 12-, or 18-week-old mice were inoculated by intraperitoneal injection with different doses of C0360/94 and observed for 4 weeks postinfection (p.i.). Mice were weighed and visually monitored for morbidity for 4 weeks postinfection. The survival analysis includes mice that were euthanized because they exhibited overwhelming signs of severe disease or weight loss below 80% of body weight. Morbidity scoring was based on a scale of 1 to 5 described by Orozco et al.: 1, healthy; 2, mild signs of lethargy; 3, lethargy, ruffled fur, and hunched posture; 4, lethargy, ruffled fur, hunched posture, and decreased mobility; 5, moribund (26) . A total of six different viral stocks (passage 2 to 4) have been used to infect AG129 mice. Characterization studies were performed as follows. Groups of 3 or 4 mice were infected with 10 7.5 FFU C0360/94 and either sacrificed at 1 to 4 days postinfection or left to be used in outcome observation of survival, morbidity, and weight loss ( Fig. 1) . At the time of sacrifice, blood, liver, spleen, and brain samples (three separate experiments with three different viral stocks) and large intestine samples (two separate experiments) were harvested.
Mouse necropsy. Following infection with 10 7.5 FFU C0360/94, groups of 3 or 4 mice were sacrificed at 1, 2, 3, and 4 days p.i. Sera were harvested from blood in serum separator tubes. Spleens were weighed to assess splenomegaly in the infected animals. Organ samples were collected into preweighed tubes. To determine viral loads, tissues were homogenized using a pestle or a syringe and 16-gauge needle. Samples were titrated using focus formation assays, and titers were expressed as FFU per gram of tissue or milliliter of serum. Because the animals were not perfused with phosphate-buffered saline (PBS) prior to tissue collection for virus titration, some virus detection may be from blood. The average limits of detection for focus titration in different tissues are as follow: serum, 10 
Complete blood count (CBC).
Blood from mice inoculated with medium or infected with 10 7.5 FFU C0360/94 was collected into EDTA anticoagulant tubes. Samples were analyzed for blood counts using a Hemavet 950TS instrument (Drew Scientific), and values from controls were com-pared to those from infected samples harvested during 1 to 3 days p.i. by using the Student t test.
Vascular leakage. Mice infected with 10 7.5 FFU C0360/94 were assessed for vascular permeability using Evans blue extravasation as previously described (18, 22) . Uninfected controls or virus-infected mice (1 to 3 days p.i.) were injected with 0.2 ml of 0.5% Evans blue solution into the tail vein. After 2 h, the mice were euthanized and perfused with approximately 60 ml of PBS. The thoracic, abdominal, and cranial cavities were visually assessed for leakage, and then organ samples were harvested into preweighed tubes with formamide for dye extraction. Extracts of liver, spleen, and large intestine were quantified for Evans blue, and values are expressed as the sample absorbance at 610 nm per gram of tissue.
Clinical chemistry. Blood (0.1 ml) from mice infected with 10 7.5 FFU C0360/94 was analyzed for blood chemistry values using a Vetscan comprehensive diagnostic rotor (Abaxis) on days 1 to 3 postinfection. A group of naive mice received no injections. For each of the 3 days of the study, there were two groups of mice: the virus-challenged group and a second group that were injected with mock culture medium. Creatinine analysis is not included because a majority of control values extended below the detection limit and a normal range could not be established.
Histology. At the time of necropsy, liver, spleen, large intestine, and brain samples were harvested and immediately fixed in 10% neutral buffered formalin. Tissues were paraffin embedded, sectioned, and stained with hematoxylin and eosin (H&E) at the UTMB Research Histopathology Core Laboratory. Sections from three groups of mice were examined: naive (day 0), mock infected, and C0360/94 infected. No differences were observed between naive (day 0) and mock-infected samples. Slides were analyzed for histopathological changes, and liver and spleen slides were semiquantitatively scored relative to naive/mock-infected controls. The liver samples were analyzed for the presence of focal necrosis (FN), nuclear pleomorphism/binucleation of hepatocytes (NP/BN), and estimated glycogen content (G). For the first two parameters, the scoring system was based on number of foci (FN) or severity (NP/BN), with a score of 0 indicating no change from controls and a score of 1 or 2 indicating increasing numbers of lesions or degrees of severity. For hepatocyte glycogen, sections were stained by using the periodic acid-Schiff (PAS) technique, and the glycogen content was taken as the overall red signal present in hepatocytes (scored from 0 to Ϫ3 depending on the degree less than control values, with a score of 0 assigned to the controls), since none of the experimental samples had more glycogen than controls. For the splenic sections, parameters analyzed included relative amounts of red pulp (RP) and white pulp (WP), fraction of white pulp involved in germinal center (GC) formation, and hematopoietic activity based on the number and density of megakaryocytes observed. The scoring scale used for these parameters was in the range Ϫ2 to ϩ2, depending on the direction and degree to which the experimental samples deviated from the controls (assigned a score of 0). The number of steps in each of these scales was determined by the ability of the pathologist to distinguish between levels based on a preliminary examination of all of the samples. Heat maps show the scores of every scored sample. All scores were subsequently plotted by day postinfection to determine the kinetic relationships of histological changes and statistical significance of the observed change.
Immunohistochemistry (IHC). Paraffin-embedded liver sections from C0360/94-infected mice were stained by the UTMB Research Histopathology Core Laboratory. Briefly, the presence of viral nonstructural protein 3 (NS3) was detected using rabbit polyclonal anti-DENV-2 NS3 (Genetex catalog no. 124252) at 1:1,000, followed by incubation with secondary and detection reagents. Liver sections from mock-infected animals served as staining controls.
Cytokine analysis. The Bio-Rad Bio-Plex Pro Mouse Cytokine 23-plex was used to test cytokine levels in 15 l of serum according to the manufacturer's instructions. Sera collected from mice at 1 to 4 days p.i. (in three separate experiments) were analyzed and compared to same-daymatched mock-infected samples (for day 4 p.i., C0360/94-infected samples were compared to day 3 p.i. mock-infected samples). Statistical analyses are described in the legend to Fig. 6 . Values for eotaxin and granulocyte-macrophage colony-stimulating factor (GM-CSF) were outside the detectable range for a majority of the mock-and virus-infected samples and were excluded from the analysis.
TNF-␣ neutralization. AG129 mice were inoculated with a lethal dose of C0360/94 (n ϭ 10). At 1, 2, and 3 days p.i., mice were intraperitoneally injected with 100 g of either anti-TNF-␣ clone MP6-XT3 (eBioscience) (n ϭ 5) or an isotype control (eBioscience) (n ϭ 5), as previously described (18), and they were observed for 4 weeks postinfection.
Virus neutralization. The antibody response of mice surviving infection was tested using 50% focus reduction neutralization titration (FRNT 50 ) assays. Briefly, sera were harvested at 29 days p.i. from terminal mouse bleeds and heat inactivated. Twofold serial serum dilutions were incubated with 50 FFU of C0360/94 for 1 h at room temperature and subsequently used to infect Vero cells in 12-well plates for virus titration using focus formation assays. The titers were analyzed using the log(inhibitor) versus normalized response-variable slope nonlinear regression model in GraphPad Prism v6.0 to acquire the FRNT 50 and 95% confidence interval.
Statistical analyses. Neutralization curves were normalized using Microsoft Excel. The 50% lethal dose (LD 50 ) was calculated using the ReedMuench method. All bar, scatter, xy, and line graphs, as well as statistical analyses (mean, median, standard error, t test, Mann-Whitney U test, 7.5 FFU of C0360/94 (n decreases because animals succumb to infection: day 0 to 3, n ϭ 15; day 4, n ϭ 11; days 5 to 7, n ϭ 2; starting on day 8, n ϭ 1).
Kruskal-Wallis analysis of variance [ANOVA] and posttest, and nonlinear regression), were generated with GraphPad Prism v6.0. Statistical significance is depicted in the figures as follows: ****, P Ͻ 0.0001; ***, 0.0001 Ͻ P Ͻ 0.001; **, 0.001 Ͻ P Ͻ 0.01; and *, 0.01 Ͻ P Ͻ 0.05.
RESULTS

DENV-3 C0360
/94 is highly lethal in 6-week-old AG129 mice. In initial studies, six-to eight-week-old AG129 mice were tested for susceptibility to infection with different low-passage-number isolates of DENV-3 C0360/94, which was originally isolated from a clinical DEN case in Thailand in 1994. Intraperitoneal infection with 10 7.5 C0360/94 focus-forming units (FFU) led to 93% mortality, with a median survival time of 4 days, whereas mice inoculated with 10 6.5 FFU C0360/94 survived infection (Fig. 1A) . These results show that C0360/94 causes lethal infection in AG129 mice with an LD 50 of 10 7.1 FFU. All animals were visually scored for morbidity on a scale of 1 to 5 (healthy to moribund) daily and received a score of 1 for the first 2 days following inoculation (Fig.  1B ). Significant changes in morbidity scores were observed in mice inoculated with 10 7.5 FFU C0360/94 from day 3 to 6 postinfection (ANOVA with Dunnett's posttest, P Ͻ 0.0001). At 3 days p.i., 67% of animals infected with 10 7.5 FFU C0360/94 (n ϭ 15) received a score of 2 or higher, indicating clinical signs of illness, and by 4 days p.i., 100% of lethal-dose-infected animals had developed severe disease. A single animal survived and completely recovered from infection by 7 days p.i. None of the animals (n ϭ 8) infected with the lower dose, 10 6.5 FFU, of C0360/94 developed clinical signs of illness. Importantly, none of the mice that succumbed developed paralysis or signs of neurological disease during the entire observation period until day 29 p.i. These data indicate that signs of illness in mice infected with 10 7.5 FFU C0360/94 peaked (mean score, 3.7) on day 4, which coincided with the median survival time.
As an additional measurement of mouse morbidity, weight change was monitored daily during acute infection. In contrast to uninfected age-matched controls, which did not exhibit weight loss (data not shown), virus-infected mice lost weight starting on day 1 p.i. (Fig. 1C) , before clinical signs were visually noted on day 3 p.i. (Fig. 1B) . Lethal-dose C0360/94 infection led to significant weight loss from days 2 to 7 p.i. (ANOVA with Dunnett's posttest, P Ͻ 0.0001). Mouse weight decreased to 77%; however, the median weight during time of illness for the group, including the single surviving mouse, was maintained at 86% due to the survivor's recovery. Mice infected with the lowest-dose inoculum of 10 6.5 FFU C0360/94 did not exhibit significant weight loss (ANOVA, P ϭ 0.6808). Weight loss data were consistent with the survival data and morbidity scores presented above.
To document that surviving animals had been infected and had mounted an immune response to the infecting virus strain, 50% focus reduction neutralization titer (FRNT 50 ) assays were performed using terminal bleed sera. Animals surviving infection with 10 6.5 (n ϭ 8) or 10 7.5 (n ϭ 1) C0360/94 had titers of 399 and 634, respectively. Together, the results from animal monitoring and survival provide evidence that AG129 mice developed disease as a result of infection with C0360/94.
Systemic detection of viral loads in C0360/94-infected AG129 mice. Lethal-dose C0360/94 infection was further examined by sacrifice of infected animals at days 1 to 4 p.i. to harvest serum and organs. The animals were monitored for weight loss and morbidity to ensure that the response in sacrificed mice was similar to that observed in the survival experiments ( Fig. 2A and B) . The mice had detectable virus on days 1 to 4 ( Fig. 2C and D) . In these studies, 90% of the mice (n ϭ 10) had detectable viremia on day 1 (10 3.3 FFU/ml) and 100% did so on days 2 (n ϭ 13), 3 (n ϭ 10), and 4 (n ϭ 4) with titers greater than 10 4.0 FFU/ml. Examination of tissues showed a time-dependent detection of virus in the liver from day 1 to 4, with titer values of 10 FFU/g. High titers (Ͼ10 4.0 FFU/g) were detected in the spleen on days 1 to 4 p.i. In the brain samples, the median viral titers were below the limit of detection on days 1 to 4. Although 30% of the samples had low-level viral titers on day 3, the results were not sufficient to yield a statistically significant titer (ANOVA, P ϭ 0.0661) in the day 3 brain tissue samples.
In order to determine whether or not inoculation with virus at low dose resulted in disseminated infection, the animals inoculated with 10 6.5 FFU C0360/94 were examined for viremia. Only 25% and 50% of the animals infected with this sublethal dose had detectable viremia (Ͼ10 1.7 FFU/ml) at 1 and 2 days p.i., respectively. Serum viral loads in these animals were Ͻ10 3.0 FFU/ml, indicating lower-level viremia (Fig. 2C) .
Taken together, the infectivity data demonstrate high viral 7.5 FFU C0360/94 were sacrificed at 1 to 4 days p.i. to harvest blood via cardiac puncture for viremia measurement; results are from three independent experiments, and each symbol represents one animal. (D) Internal organ samples were harvested via necropsy and homogenized, and virus was titrated; results for liver, spleen, and brain are from three separate experiments and stocks, and those for large intestine are from two experiments and stocks. ANOVA was used to establish significant differences in the titers: serum, spleen, brain, not significant; liver and large intestine, P ϭ 0.0006. Asterisks indicate significance determined by Tukey's multiple comparison. Serum titers are expressed as log 10 FFU/ml and organ titers as log 10 FFU/g of tissue. Symbols represent individual sample titers; horizontal lines represent the median daily titer. loads in the sera, livers, spleens, and large intestines of mice infected with a lethal dose of C0360/94, indicative of systemic DENV infection of AG129 mice, whereas, mice infected with a sublethal dose of virus had lower viremia. The transient detection of low virus titers in the brains of a small proportion of the animals combined with the absence of neurological signs in mice infected with C0360/94 strongly suggested that the animals were not dying of neurological disease.
C0360/94 infection decreases platelet and leukocyte counts. The ability of lethal C0360/94 infection to alter blood cell counts in AG129 mice was examined, as this is a hallmark feature of DEN in humans. Blood samples from mock-infected (n ϭ 10) or C0360/94-infected (n ϭ 9) mice were collected at 1 to 3 days p.i., and the results from all 3 days were combined (Fig. 3) . CBC values show that, compared to controls, C0360/94-infected AG129 mice developed thrombocytopenia (P ϭ 0.0088) and leukopenia (P ϭ 0.0060), including decreased lymphocyte counts (P Ͻ 0.0001). However, virus-infected mice failed to show an increase in hematocrit levels (P ϭ 0.6232). These results indicate that C0360/94 infection leads AG129 mice to develop some signs of human DEN.
Vascular leakage occurs in C0360/94-infected animals. Vascular leakage is characteristic of human DEN, so the ability of C0360/94 to cause permeability was assessed in AG129 mice. Lethal-dose-infected animals were subjected to an Evans blue extravasation assay. Liver, spleen, and large intestine samples from uninfected mice (n ϭ 10) and mice infected at 1 (n ϭ 4) and 2 (n ϭ 7) days p.i. were harvested and subjected to quantitative analysis (Fig. 4A) . The results show the presence of statistically significant (by ANOVA) leakage into the livers (P Ͻ 0.0001) and large intestines (P ϭ 0.0007) of infected animals at 1 and 2 days p.i. compared to results for uninfected controls. Leakage was not detected in the spleens (P ϭ 0.1131). Furthermore, there was a statistically significant rise in the leakage of the liver from day 1 to day 2 (ANOVA with Tukey's posttest, P Ͻ 0.01), indicating that leakage into this tissue increases with time. Unfortunately, too few animals (n ϭ 2) on day 3 were successfully assayed for Evans blue extravasation to include in the analysis. However, an image showing the organs harvested from an animal at 3 days p.i. shows that the liver and intestine contain blue dye (Fig. 4B) , but organs from a control animal do not. Furthermore, examination of the mouse brains showed that no detectable leakage occurred in the brains of virus-infected animals (Fig. 4C) , thus supporting the absence of neurological involvement during C0360/94 infection. C0360/94 infection alters AG129 mouse blood chemistry. The effect of lethal-dose C0360/94 infection on the chemical balance and metabolism of the mice was assessed using blood chemistries. Samples harvested from mice at 1 to 3 days p.i. were compared to those from age-matched naive controls (Fig. 5) using ANOVA with Tukey's posttest. Decreased albumin levels have been associated with dengue infection in humans, and significantly lower serum albumin was present at 2 days p.i. (P Ͻ 0.001), from 4.2 g/dl in control mice to 3.1 g/dl in infected mice; at 3 days p.i., albumin levels also trended low, but the difference was not statistically significant. Levels of electrolytes, such as potassium (P Ͻ 0.05), were also altered by C0360/94 infection. Sodium levels increased significantly at 3 days p.i. (P Ͻ 0.05). Calcium was significantly elevated at 1, 2, and 3 days p.i. (P Ͻ 0.0001, P Ͻ 0.001, and P Ͻ 0.0001, respectively), from approximately 10.0 mg/dl for con-trols to approximately 11.5 mg/dl for infected animals. Other indicators of organ disease, such as amylase (P Ͻ 0.05) and alkaline phosphatase (P Ͻ 0.0001), were significantly altered. However, no significant changes (P Ͼ 0.05) were observed in blood urea nitrogen, total bilirubin, and alanine aminotransferase, the last of which is associated with clinical dengue infection. Both globulin and total protein were significantly elevated at 2 and 3 days p.i. (P Ͻ 0.0001). Overall, the blood chemistry results indicated decreased albumin on day 2 and an imbalance of electrolytes paired with a rise in total protein and globulin.
C0360/94 infection results in histopathology in AG129 mice. Tissues from mice inoculated with the lethal dose of C0360/94 were examined for signs of disease at 1 to 4 days p.i. Hematoxylin and eosin (H&E)-stained sections from naive, mock-infected, and virus-infected animals were subjected to detailed analysis. First, no histopathological changes were observed in mouse brain sections (data not shown). Second, no major differences were present in the large intestines of virus-infected animals compared to naive or mock-infected controls. A few areas in the submucosae of virus-infected animal sections contained eosinophils (and one to two neutrophils) but with the absence of inflammation, proliferation, or damage (data not shown). However, significant histopathology was observed in spleen and liver sections (Fig. 6A) . Several parameters were scored relative to mock-infected controls using semiquantitative rating scales (described in Materials and Methods). A heat map depiction (Fig. 6C ) and graphical representation ( Fig. 6D and E) of the slide scores provided a context for the micrographs shown in Fig. 6A .
The spleens of mock-infected mice showed normal organ architecture, whereas several changes were observed in virus-infected samples (Fig. 6A, left panels) . Some increases in spleen red pulp content were observed, possibly due to congestion, but 65% of infected spleens had a decreased red pulp content throughout the course of infection, dipping to Ϫ2 on day 4. This change was accompanied with an increase in the white pulp content in 74% of samples, which was significant on day 4 (ANOVA with Dunnett's posttest, 0.01 Ͻ P Ͻ 0.05), and an increase in the fraction of the white pulp involved in germinal center cell transformation in 96% of samples (ANOVA, P ϭ 0.0002) with a time-dependent increase. Furthermore, the hematopoietic cell content (using megakaryocytes as an index) reached 1 at 1 day p.i. and then decreased to 0 on day 4 (Fig. 6D) .
Histopathological changes were also observed in the liver (Fig.  6A, right panels) . Nuclear pleomorphism and binucleation of hepatocytes (NP/BN) increased steadily (ANOVA, P ϭ 0.0002) throughout the course of infection and were observed in 71% of samples at 1 day p.i. and 100% of samples at 2 to 4 days p.i. (Fig. 6C  and E) . Additionally, focal necrosis of the liver was observed in sections at 1 to 3 days p.i. (29%, 43%, and 14%, respectively). Furthermore, hepatocyte vacuolation indicated that glycogen levels were altered, so periodic acid-Schiff (PAS) staining was performed (Fig. 6B) . Slides from infected samples were scored relative to mock-infected samples, and a decrease in liver glycogen was observed at 1, 3, and 4 days p.i. (ANOVA, P Ͻ 0.0001) (Fig. 6F) .
Splenomegaly has been observed in 12 to 34% of human DENV infections and in other mouse models of DEN (27, 28, 29, 30, 31) . Spleens were harvested from mice, and the total spleen weight was compared to the whole-animal weight on 1 to 4 days p.i. (Fig. 6G) . Infection led to a statistically significant increase in spleen weight (ANOVA, P Ͻ 0.0001) by 1 day p.i., from 0.28% to 0.52% of body weight, and spleen weight peaked at 3 days p.i. (ANOVA with Dunnett's posttest, P Ͻ 0.0001) at 0.75% of body weight. These results show that mice develop splenomegaly within 1 day of infection with a lethal dose of C0360/94.
Together, these results indicated that lethal-dose C0360/94 infection induced gross pathology and histopathological changes in the spleen and liver but not in the brain or large intestine. The lack of histopathological change in the brain was consistent with the lack of detectable viral infectivity in the brain (Fig. 2C) .
C0360/94 replicates in the liver. In order to detect replicating C0360/94 in AG129 mouse tissues, liver sections were stained for the nonstructural protein NS3. Although the antibody (GTX 124252) was generated against DENV-2, preliminary Western blot analysis indicated that it recognized C0360/94 (data not shown). IHC staining was performed on liver sections from lethaldose-infected (1 and 2 days p.i.) and mock-infected animals (Fig.  7) . Virus-infected Kupffer cells were positive on both days, and several virus-positive cells were detected in any given field. The signal was restricted to Kupffer cells in the sinusoids, as NS3 was not detected in any other cell type in the liver sections. The IHC results suggest that the tropism of C0360/94 in AG129 mice is for macrophage-like cells.
C0360/94 infection results in altered cytokine expression in AG129 mice. Altered expression of several cytokines has been observed in human samples from patients diagnosed with DF or DHF/DSS (3, 32) and in other mouse models of infection (18) . Sera harvested from lethal-dose-infected mice were analyzed using Bioplex and compared to sera from same-day-matched mock-infected controls with Mann-Whitney U tests. Additionally, Kruskal-Wallis tests with Dunn's multiple comparisons were performed to detect changes in cytokine values between days (Fig.  8) . The chemokines keratinocyte chemoattractant (KC) (mouse interleukin-8 [IL-8] ortholog), monocyte chemoattractant protein-1 (MCP-1) (chemokine ligand 2 [CCL2]), macrophage inflammatory protein-1␣ (MIP-1␣) (CCL3), MIP-1␤ (CCL4), and RANTES (regulated on activation, normal T cell expressed and secreted) (CCL5) were significantly elevated every day compared to levels in mock infection. Interestingly, levels of KC, CCL2, CCL3, and CCL4 were significantly higher on day 1 than on day 2 or 3, and that of CCL3 rose again on day 4. Levels of inflammatory cytokines IL-1␣, IL-6, IFN-␥, IL-12p40, and TNF-␣ increased during infection compared to mock infection; IL-12p70 was elevated only at 1 day p.i. TNF-␣, a hallmark of the DENV-2 mouse model, was elevated on all days postinfection. The levels of IL-6 and IFN-␥ were significantly increased on day 4 compared to the other days. Changes in serum levels of growth, proliferation, and differentiation cytokines, i.e., granulocyte colony-stimulating factor (G-CSF), IL-3, IL-4, IL-9, IL-10, IL-13, and IL-17A, were also detected on at least 2 days. Both IL-2 and IL-4 had significant decreases from day 1 to day 3 postinfection. There were no changes in the amount of IL-1␤, IL-2, or IL-5 (data not shown). The cytokine profile data indicate that infection with C0360/94 leads to innate immune response changes similar to those seen in DEN disease in humans.
TNF-␣ mediates C0360/94-induced lethality. TNF-␣ has been implicated in the lethality of DENV-2 infection of AG129 mice, and the above results show its elevated levels in the sera of C0360/ 94-infected mice. Therefore, the role of TNF-␣ was further analyzed in this model. Anti-TNF-␣ or isotype antibody was administered to C0360/94-infected animals at 1, 2, and 3 days p.i. Survival analysis results show that antibody neutralization of TNF-␣ rescued 100% of mice infected with lethal-dose C0360/94 (n ϭ 5) (Fig. 9) , whereas isotype antibody treatment resulted in mortality of all of those animals (n ϭ 5) (log rank test, P ϭ 0.0027). These results demonstrate that TNF-␣ plays a key role in the mechanism of C0360/94-mediated lethality in AG129 mice.
Characterization of C0360/94 infection in 12-and 18-weekold AG129 mice. Studies were extended to assess the impact of age on the susceptibility of mice to C0360/94 infection. Mice at 6, 12, and 18 weeks old were infected with 10 7.5 FFU C0360/94. Both 6-week-old (n ϭ 11) and 12-week-old (n ϭ 5) mice had a median survival time of 4 days and similar mortality rates of 91% and 80%, respectively, which were not significantly different (log rank test, P ϭ 0.4579) (Fig. 10A) , whereas 18-week-old mice (n ϭ 16) had a median survival time of 5 days and mortality of 56%, which was significantly different from the mortality of 6-week-old mice (log rank test, P ϭ 0.0155) but not from that of 12-week-old mice. The 6-, 12-, and 18-week-old mice exhibited morbidity at 3 to 6 days p.i. (Fig. 10B) , and peak weight loss occurred at 4 to 5 days p.i., as mouse weights decreased to 80%, 87%, and 93% of normal body weight, respectively (Fig. 10C) . Interestingly, the 18-week-old weight range dropped below 90% on day 2 to 9 p.i., but the median values were maintained above this mark due to weight gain in some animals. All of the surviving mice regained body weight to normal levels. One group each of 6-and 12-week-old animals (n ϭ 5) was bled at 3 days p.i. to compare viremia levels. All of the animals, except for one 12-week-old mouse, had detectable virus titers. Specifically, the infective titers in 6-and 12-week-old mice were 10 5.5 and 10 5.0 FFU/ml, respectively, which were not significantly different (t test, P ϭ 0.3495). Lastly, all mice surviving infection induced neutralizing antibodies to C0360/94 virus; sera from 6 (n ϭ 1)-, 12 (n ϭ 1)-, and 18 (n ϭ 6)-week-old mice exhibited mean FRNT 50 titers of 659, 695, and 287, respectively, compared to those in naive AG129 mouse serum (data not shown). Taken together, these data show that infection with 10 7.5 FFU C0360/94 in 12-week-old mice resulted in clinical signs similar to those in 6-week old mice, while 18-week-old mice were susceptible to C0360/94, albeit at a lower level.
DISCUSSION
The present study reports a lethal DENV-3 model in AG129 mice in which animals develop disseminated disease in the absence of neurological signs. Significantly, this paper is also the first to describe a mouse-lethal strain based on a low-passage-number, nonmouse-adapted isolate of a DENV. This raises the potential that there could be low-passage-number isolates of each of the four DENVs that are virulent in the AG129 mouse model.
Detailed characterization of serum, tissues, and pathology demonstrate many similarities between the DENV-3 AG129 model described here and previously reported DENV-2 AG129 models. DENV-3 strain C0360/94 was lethal in AG129 mice with an LD 50 of 10 7.1 FFU, which is a dose similar to that required for lethal, non-antibody-dependent enhancement-induced disease in DENV-2 AG129 mouse models (18) . Inoculation with lethal-dose C0360/94 resulted in a high-titer viremia (greater than 10 4.0 FFU/ml on days 2 to 4), which is consistent with the observation that higher viremia levels in humans are associated with severe DEN (33) , and all of the C0360/94 tissue viral titers were comparable to those caused by the DENV-2 D2S10 model, with the exception of brain titers. Overall, the pathological changes indicate that C0360/94 induces systemic effects in AG129 mice.
In humans, DENV infection leads to altered blood cell profiles. AG129 mice infected with the lethal dose of C0360/94 exhibited decreased platelet counts (P ϭ 0.0088), a hallmark of DEN in humans, accompanied by leukopenia (P ϭ 0.0060), which also included lymphopenia. Furthermore, an Evans blue assay showed that the animals developed vascular leakage into the liver as early as 1 day p.i. (P Ͻ 0.0001) and into the large intestine at 2 days p.i. rise on day 2. No significant leakage into spleen tissues was detected, which differs from the results obtained with DENV-2 models. However, it is possible that leakage into spleens of C0360/ 94-infected mice at a moribund state, when data were not gathered, did occur. These results are consistent with the disease reported in humans and suggest that the mechanism of C0360/94-mediated death of AG129 mice involves altered circulatory manifestations.
Detailed blood chemistry analysis showed that the mice had increased levels of electrolytes, globulin, and total protein. Calcium was elevated on all of the days (P Ͻ 0.001), with sodium (P ϭ 0.0181) and potassium (P ϭ 0.0074) levels increasing at 3 days p.i. Also, serum albumin levels decreased in the C0360/94-infected mice on day 2 (P ϭ 0.0132), which is consistent with the DENV-2 D2Y98P AG129 model and human infections (34, 35) . Human alanine aminotransferase (ALT) and aspartate transaminase (AST) levels are often increased during DENV infection. In the present study, we analyzed mouse ALT, which was slightly elevated on day 1 (from 38 to 50 U/liter), but the difference was not statistically significant (P ϭ 0.4644) and did not rise to the level that has been observed in humans or DENV-2 AG129 mouse models (22, 36) . However, the rapid course of disseminated DENV infection in our study may not permit a direct comparison of such parameters with the DENV-2 mouse model, as the D2Y98P-infected animals exhibit heightened ALT levels beginning at 6 days p.i. Though not identical to human DEN samples, several clinical chemistry values of C0360/94-infected mice indicate a metabolic response to C0360/94 infection, and the blood count data indicate that the mice experience features observed in DEN patients, suggesting similarities in the mechanism of C0360/ 94-mediated lethal disease.
Tissue H&E sections from infected animals were examined for histopathological changes. Several parameters were measured in spleen and liver slides, but no overt differences were observed in brain and large intestine samples (Fig. 6 ). The semiquantitative scoring (Fig. 6C ) of liver and spleen sections provided a platform to determine the kinetics of histological changes, including splenic white pulp and red pulp content ( Fig. 6D and E) . This is consistent with DENV-2 AG129 studies that have reported destruction of splenic architecture and hepatic necrosis (18, 34) . The results indicate the presence of a response to infection within 1 day p.i. that includes liver damage, as well as immune activation in the form of increased cell proliferation and the expansion of large lymphocytes and germinal center cells into the red pulp. Furthermore, all of the infected mice developed splenomegaly (P Ͻ 0.0001), which has also been observed in some human cases of disease and in DENV-2 mouse model samples (22, 27, 28, 29, 37) . Another interesting observation was the sharp decrease in the glycogen content (P Ͻ 0.0001) of hepatocytes ( Fig. 6B and G) beginning 1 day  p. i., which has not been evaluated in other DENV models. This loss in glycogen stores may correlate with the clinical status of the mice, which lose a significant amount of weight before succumbing to infection.
Studies regarding the cellular tropism of DENV have identified macrophages and dendritic cells as the sites of infection and replication in humans, with some reports citing staining of hepatocytes and endothelium (38, 39) in humans and/or mice. Recently, a detailed analysis of human DEN autopsy cases found that viral structural and nonstructural protein staining was positive in hepatocytes and Kupffer cells in the liver and in immune cells in the spleen, while no antigen was detected in any endothelial cells (40) . In the present study, IHC staining revealed that the tropism of C0360/94 is restricted to Kupffer cells, because no signal was detected in hepatocytes, sinusoidal cells, or endothelial cells. Without employing a double-staining technique the identity of the stained cells cannot be proven; however, the morphology is consistent with that of Kupffer cells.
Interestingly, the DENV-2 AG129 models have shown damage to the small intestine as a result of lethal infection. In the present study, only the large intestine was evaluated, and no major changes were observed. The absence of intestinal pathology may indicate a difference in the tropism or severity of C0360/94-mediated disease.
Mouse infection and human sample studies have examined the acute cytokine response to DENV (18, 32, 41) . Bioplex analysis of lethal-dose C0360/94-infected animals showed that chemokines, inflammatory cytokines, and growth, proliferation, and differentiation cytokines (with the exception of IL-1␤ and IL-5) had statistically significantly elevated levels compared to those in mockinfected controls. Several of these cytokines have been identified as markers of DENV infection in humans, including IL-6, IL-10, IFN-␥, and TNF-␣. Notably IL-6, IL-10, and IFN-␥ increased as infection progressed, while TNF-␣ was elevated at all times examined. Furthermore, TNF-␣ has been specifically implicated as contributing to the disease progression of AG129 mice infected with DENV-2 strain S10 (18) . In that model, D2S10 (compared to PL046) induced heightened TNF-␣ levels at 3 days p.i. but not on days 1 and 2. Moreover, the DENV-2 D2Y98P model is also characterized by a cytokine storm with heightened levels of IL-6, TNF-␣, and IFN-␥ (22) . Similar to the D2S10-infected AG129 mice, D2Y98P infection led to a time-dependent increase in TNF-␣ until death. Also, elevated serum IL-6, IL-10, and TNF-␣ were detected in the DENV-2 strain S221 ADE model (20) . The serum characterization data indicate that DENV-3 infected AG129 mice mount an acute immune response similar to that observed in humans and DENV-2 mouse models and that the contribution of TNF-␣ to the mechanism of systemic C0360/94 infection is kinetically distinct from that observed in the DENV-2 AG129 mouse models.
Further analysis of TNF-␣ involvement in the C0360/94 model included an antibody neutralization assay. The results showed that all mice treated with anti-TNF-␣ survived infection. The data from the present study differ from the published neutralization results of DENV-2 models. Specifically, anti-TNF-␣ only delayed mortality caused by D2S10 infection, but mice infected with C0360/94 were rescued completely. These differences may be associated with the differences in the elevation of TNF-␣ when comparing DENV-2 to C0360/94 infection. In the former, TNF-␣ increases over time, but in the latter, the levels are high earlier during the course of infection. Therefore, DENV-2-infected mice may experience diminished benefits from antibody administration, but the C0360/94-infected animals undergo TNF-␣ neutralization at a time during infection when the damage is reversible, thus leading to recovery.
In conclusion, our study describes the development of a nonmouse-adapted, nonneurovirulent DENV-3 lethality mouse model. Detailed characterization of blood, serum, tissues, and pathology demonstrate similarities between mouse signs of illness and human DEN disease, including decreased platelets and leukocytes, high viral titers, increased cytokine levels, and splenomegaly. These data suggest a systemic mechanism of C0360/94-mediated lethality that involves immediate infection and an overwhelming immune response evidenced by circulating cytokines and histopathology. The C0360/94 model in AG129 mice has important applications to investigate DENV pathogenesis and to evaluate candidate vaccines and antivirals.
